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Personalized medicine uses various individual characteristics to guide medical decisions.
Apolipoprotein (ApoE), the most studied polymorphism in humans, has been associated
with several diseases. The purpose of this review is to elucidate the potential role of ApoE
polymorphisms in personalized medicine, with a specific focus on neurodegenerative
diseases, by giving an overview of its influence on disease risk assessment, diagnosis,
prognosis, and therapy. This review is not a systematic inventory of the literature, but
rather a summary and discussion of novel, influential and promising works in the field
of ApoE research that could be valuable for personalized medicine. Empirical evidence
suggests that ApoE genotype informs pre-symptomatic risk for a wide variety of diseases,
is valuable for the diagnosis of type III dysbetalipoproteinemia, increases risk of dementia
in neurodegenerative diseases, and is associated with a poor prognosis following acute
brain damage. ApoE status appears to influence the efficacy of certain drugs, outcome
of clinical trials, and might also give insight into disease prevention. Assessing ApoE
genotype might therefore help to guide medical decisions in clinical practice.
Keywords: ApoE, cardiovascular diseases, Alzheimer disease, neurodegenerative diseases, risk, diagnosis,
prognosis, treatment
INTRODUCTION
PERSONALIZED MEDICINE AND GENETIC
Personalized medicine refers to medical care that uses individual
characteristics, such as family and personal history, gene, protein,
or environmental information to facilitate a global analysis of
individual risk evaluation, diagnosis and prognosis, and improve
therapeutic and preventive approaches for patients (Offit, 2011).
Personalized medicine would therefore guide medical decisions.
Even though the practice of personalized medicine is not new,
there is an increasing enthusiasm in this approach which can be
attributed to the exploding field of genetic research.
Apolipoprotein (ApoE) is a protein that is well known for its
key roles in the transport of cholesterol and other lipids in blood
circulation and central nervous system (CNS). Since its identifi-
cation in 1973 (Shore and Shore, 1973), ApoE has become one
of the most widely studied gene variants, not only for cardio-
vascular disorders but also in relation to several other medical
conditions such as neurodegenerative and autoimmune diseases
(Mahley, 1988; Mahley et al., 2009; Verghese et al., 2011). Given
its broad biological role, ApoE may therefore become a major
variable of preventive medicine. This review aims to summa-
rize the role of ApoE in components of personalized medicine,
including the individual risk prediction, diagnosis, prognosis, and
treatment of associated diseases. This review is intended to sum-
marize and discuss novel, influential and promising works in the
field with a specific, but not exclusive, focus on neurodegenerative
diseases.
APOLIPOPROTEIN E BASIC STRUCTURES AND FUNCTION
ApoE includes three common isoforms (ApoE2, ApoE3, ApoE4),
coded by three codominant alleles (e2, e3, e4). Hence, six pheno-
types commonly exist in the general population, three homozy-
gous (ApoE2/2, ApoE3/3, and ApoE4/4) and three heterozygous
(ApoE2/3, ApoE2/4, and ApoE3/4). ApoE2 and ApoE4 differ
from ApoE3 by a single amino acid substitution. While ApoE3
contains cysteine at position 112 and arginine at position 158,
the arginine is substituted by a cysteine in ApoE2 carriers and
the cysteine is substituted by an arginine in ApoE4 carriers
(Weisgraber et al., 1982;Mahley, 1988). This arginine substitution
results in an interaction between ApoE4 amino- and carboxyl-
terminal domains, known as “domain interaction” (Mahley
and Huang, 2009). The structural difference due to domain
interaction is believed to play a role in the altered function
of ApoeE4.
ApoE is synthesized predominantly in the liver but is also
found in the brain, spleen, lung, kidney, ovary, testis, periph-
eral nerves and muscular tissues (Zhang et al., 2011). In the
brain, ApoE is produced by astrocytes and, to a minor extent,
by microglia (Pitas et al., 1987; Grehan et al., 2001), and can
also be produced by neurons in response to neuronal injury
or stress (Mahley and Huang, 2012a). ApoE’s principal known
function is to transport cholesterol and other lipids in blood cir-
culation and the CNS by binding to ApoE receptors on their
cell surface (Mahley, 1988). ApoE is also essential to maintain
the structural integrity of lipoproteins, stabilize, and solubilize
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liproproteins in the blood, and to serve as cofactors in enzymatic
reaction (Eichner et al., 2002). In the brain, cholesterol plays a
crucial role in myelin production and is an essential component
ofmembrane sheaths, brain development, neuronalmaintenance,
neuronal repair, and long-term synaptic plasticity (Mauch et al.,
2001; Bu, 2009; Mahley et al., 2009; Leduc et al., 2011).
RISK ASSESSMENT
Because of its key role in the regulation of lipid metabolism ApoE
was first recognized for its role in cardiovascular diseases (CVD).
While the ApoE3 isoform is not associated with an increased risk
of CVD, the ApoE4 isoform is a major risk factor for CVD, such
as coronary heart disease, arrhythmias, and stroke (Lahoz et al.,
2001; Eichner et al., 2002; Song et al., 2004; Mahley et al., 2009).
ApoE2 has a more ambiguous relationship with CVD as it has
been associated with both an increased (Mahley et al., 1999; Lahoz
et al., 2001) and reduced (Bennet et al., 2007) risk of CVD. This
duality found in the ApoE2 isoform suggests that the adverse or
beneficial impact of ApoE2, and potentially ApoE4, on disease
risk is influenced by it interaction with other genetic or envi-
ronmental factors (Lahoz et al., 2001; Elosua et al., 2003; Mahley
et al., 2009).
It is now well recognized that ApoE is also associated with a
variety of other diseases. ApoE4 for instance is the most impor-
tant genetic risk factor for late onset Alzheimer Disease (AD)
(Poirier et al., 1993; Leduc et al., 2011; Verghese et al., 2011) with
ApoE4 carriers having a 4 to 12-fold increased risk of developing
AD when compared to non-carriers (Corder et al., 1993, 1994;
Bertram and Tanzi, 2008; Mahley and Huang, 2012a). The ApoE2
isoform on the other hand is protective against AD (Corder et al.,
1993, 1994). How these isoforms differently affect the risk of AD is
not fully understood. Several mechanisms have been implicated.
One potential mechanism is via accumulation and/or clearance of
amyloid-β (Aβ, a hallmark of AD) from the brain because ApoE4
has been associated with greater Aβ burden (Strittmatter et al.,
1993; Ye et al., 2005; Drzezga et al., 2009) and ApoE2 with lower
Aβ burden (Jiang et al., 2008; Morris et al., 2010). It is well estab-
lished that ApoE binds directly to the Aβ peptide. Compared to
the other isoforms, ApoE4 binds to Aβ with lower affinity, which
might result in less efficient clearing of Aβ through the cell sur-
face (Ladu et al., 1994; Yang et al., 1999; Tokuda et al., 2000). In
the same line, ApoE4 is associated with slower transport of Aβ
across the blood-brain barrier (BBB), causing greater Aβ reten-
tion in mice brains (Deane et al., 2008). ApoE4 is also associated
with BBB dysfunction, whichmight lead to Aβ accumulation, and
also to a reduction in cerebral blood flow and hypoxia, two con-
ditions that enhance brain vulnerability (Zlokovic, 2011). While
several routes exist for the clearance of Aβ, clearance directly into
the blood seems to be the predominant pathway in the human
brain (Bell and Zlokovic, 2009; Bell et al., 2012). Accordingly,
vessel wall thickness and reduced cerebral blood flow may result
in Aβ accumulation. Supporting this idea, ApoE4 carriers are
known to have higher accumulation of Aβ in cerebral blood ves-
sels, a condition known as cerebral amyloid angiopathy (CAA)
(Verghese et al., 2011). ApoE4 is also associated with greater neu-
ronal inflammation (Grainger et al., 2004; Guo et al., 2004; Kim
et al., 2009; Leduc et al., 2011) and less efficient neuronal repair
(Mauch et al., 2001; Bu, 2009; Mahley et al., 2009; Leduc et al.,
2011), two other conditions that might influence the risk of AD.
Finally, in response to neuronal injury, neuron-ApoE4 produc-
tion can generate neurotoxic fragments that exacerbate neuronal
toxicity, increase tau phosphorylation, NFT formation, neuronal
mitochondrial dysfunction, and decrease GABAergic interneuron
selectivity (Mahley and Huang, 2012a; Liu et al., 2013).
The association of ApoEwith other neurodegenerative diseases
is less clear. Recent meta analyses suggest that ApoE4 carriers
might be more susceptible to Creutzfeldt–Jakob disease (Wei
et al., 2014). ApoE2 in turn might increase the risk of age-related
macular degeneration (Leduc et al., 2011) and Parkinson disease
(Huang et al., 2004) highlighting again the ambiguous role of
ApoE2.
As it can be seen in Table 1, the impact of ApoE goes far
beyond the boundary of CVD and neurodegenerative diseases.
Links have been suggested for instance between ApoE4 and the
susceptibility to malaria, viral infections such as herpes simplex
virus (HSV), human immunodeficiency virus (HIV) (Mahley
et al., 2009; Zhang et al., 2011), cancer (Porrata-Doria et al., 2010;
Kulminski et al., 2011; Saadat, 2012), and gallbladder stone dis-
ease (Xue et al., 2012). Even if these last associations are not always
consistent between studies, all together they suggest that ApoE
influences the risk of a variety of diseases which supports the idea
that ApoE influences human health via multiple pathways.
At present the utility of determining ApoE genotype in every-
day practice is questionable for two reasons: ApoE is principally a
risk factor and not a causal factor, and inconsistencies remain in
the literature, particularly for diseases other than CVD and AD.
Understanding the cause of these inconsistencies, or why some
persons do not develop a specific disease, might however yield
great potential for disease prevention. Indeed, for some diseases,
ApoE might only have a detrimental effect under specific circum-
stances or when interacting with other factors. While ApoE alone
might therefore not be useful to assess risk of developing a spe-
cific disease, it could be included in an integrated risk evaluation
metric. The association between the e4 allele and a poor vascu-
lar health for instance seems to be stronger in the presence of
life stress factors and habits such as obesity, alcohol consump-
tion, and smoking (Corella et al., 2001; Djousse et al., 2002; Zeng
et al., 2011). Indeed weight gain and obesity appear to have a
particularly severe effect on ApoE4 carriers, and have been associ-
ated with increases in triglycerides, β lipoprotein (Gueguen et al.,
1989), total insulin and LDL cholesterol levels (Marques-Vidal
et al., 2003). If clinicians possessed this knowledge and ApoE
genotype information, they could provide more patient-specific
treatment advice that would particularly help ApoE4 carriers
reduce their risk of CVD. Another example would be the inter-
action between ApoE and lifestyle on the risk of AD. Increased
physical activities and good vascular health appear to reduce the
negative effect of ApoE4 on Aβ and AD (Niti et al., 2008; Ferrari
et al., 2013). Physical activity also reduces the rate of hippocampal
atrophy in ApoE4 carriers, an effect that was not observed in non-
carriers (Smith et al., 2014). The hippocampus is a key structure
for episodic memory formation (Villeneuve and Belleville, 2012),
and is particularly sensitive to AD. Lifetime cognitive activity also
seems to reduce the negative impact of ApoE on Aβ burden, since
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Table 1 | Association of ApoE to pre-symptomatic risk, prognosis, and response to treatment.
Phenotype Risk Prognosis Treatment
HYPERLIPIDEMIA (Mahley, 1988; Mahley et al., 1999; Maitland-Van Der Zee et al., 2003; Nieminen et al., 2008; Dergunov, 2011)
Familial hyperlipidemia and
hypercholesterolemia
E2 (−) Highest response to lipid-lowering therapy
E4 + Lowest response to lipid-lowering therapy
Lowest compliance to treatment
Highest response to low fat diet
Familial dysbetalipoproteinemia E2 +
E4
CARDIOVASCULAR DISEASES (Lahoz et al., 2001; Eichner et al., 2002; Masson et al., 2003; Song et al., 2004;
Martinez-Gonzalez and Sudlow, 2006; Stehle et al., 2008; Mahley et al., 2009; Guo et al., 2011; Khan et al., 2013; Rannikmae et al., 2013)
Stroke E2
E4 (+) Worst prognosis
↑ Risk of death*
Coronary heart disease E2 (−)
E4 + ↑ Risk of death
Cerebral amyloid angiopathy
(CAA)
E2 ↑ Risk hemorrhage
E4 + ↑ Risk hemorrhage
↑ Severity
↑ Risk death
NEURODEGENERATIVE DISEASES (Poirier et al., 1993; De La Fuente-Fernandez et al., 1999; Bedlack et al., 2000; Leduc et al., 2011;
Verghese et al., 2011; Panza et al., 2012; Yin et al., 2012)
Alzheimer disease (AD) E2 − Later onset
E4 + Earlier onset
↑ Neuropsychiatric symptoms
Cognition: Lowest response or no improvement
in persons with dementia but higher response in
persons with mild cognitive impairment
Biomarkers (amyloid and CSF tau): higher
response in persons with dementia
Vascular disease-associated
cognitive impairment
E2
E4 ↑ Risk dementia
Lewy body disease E2
E4 (+) ↑ Risk dementia
Pick’s disease E2
E4 Earlier onset
↑ Risk dementia
Corticobasal degeneration E2
E4 ↑ Risk dementia
Down’syndrome E2
E4 Faster progression
↑ Risk dementia
Parkinson’s disease (PD) E2 +
↑ Risk dementia E4/4: ↑ Drug-induced hallucination
Amyotrophic lateral sclerosis
(ALS)
E2 Later onset
E4 Earlier onset
Worst prognosis
Age-related macular degeneration E2 (+) Earlier onset
E4 (−) Later onset
(Continued)
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Table 1 | Continued
Phenotype Risk Prognosis Treatment
AUTOIMMUNE DISEASES (Corder et al., 1998; Roselaar and Daugherty, 1998; De Bont et al., 1999; Mahley et al., 2009; Vitek et al., 2009;
Kuhlmann et al., 2010; Zhang et al., 2011)
Human immunodeficiency virus
(HIV)
E2 (↑ Risk hypertriglyceridemia)
E4 (+) ↑ Risk dementia
↑ Risk Peripheral neuropathy
↑ Risk AIDS
(↑ Risk hypertriglyceridemia)
Acquired immunodeficiency
syndrome (AIDS)
E2
E4 + Worst prognosis
Hepatitis C virus E2 E3 and E2: ↑ Risk chronic
infection
E4 (Lowest response to antiviral therapy)
OTHER [TRAUMATIC BRAIN INJURY (Lichtman et al., 2000; Chamelian et al., 2004; Crawford et al., 2009; Hiekkanen et al., 2009;
Ponsford et al., 2011); DIABETES MELLITUS (Tsuzuki et al., 1998; Bedlack et al., 2003; Saito et al., 2004; Yin et al., 2013); CANCER
(Ahles et al., 2003; Porrata-Doria et al., 2010; Kulminski et al., 2011; Saadat, 2012); DEPRESSION (Irie et al., 2008; Kim et al., 2010, 2011;
Meng and D’Arcy, 2013)]
Traumatic brain injury E2
E4 Worst prognosis
Diabetes mellitus E2
E4 ↑ Risk diabetic neuropathy Best response to low fat diet
Cancer E2
E4 (+) (E4: ↑ side effect following chemotherapy)
Depression E2
E4 ↑ Risk dementia
Creutzfeldt-Jakob disease, gallbladder stone disease, Huntington’s disease, inclusion-body myositis, cerebral palsy, progressive supranuclear palsy, temporal lobe
epilepsy multiple system atrophy, multiple sclerosis, frontotemporal dementia, malaria and herpes simplex virus need further exploration (Bu, 2009; Leduc et al.,
2011; Verghese et al., 2011; Xue et al., 2012; Yin et al., 2012; Rubino et al., 2013; Wei et al., 2014). *In subarachnoid hemorrhage and intracerebral hemorrhage stroke;
+, increased risk; −, decreased risk; (parentheses), limited, or conflicting results exist.
ApoE4 carriers that report high lifetime cognitive activity have
similar Aβ brain burden than non-carriers (Wirth et al., 2014).
Incorporating these findings into medical practice would suggest
that physical and cognitive activity could be used as preventive
activities to reduce the risk of AD in ApoE4 carriers. With no
current treatment for AD, and with ApoE being the main risk
factor for this disease, better understanding of the factors that
interact with ApoE-related risk to postpone the development of
the disease is needed given their potential implication in pre-
ventive medicine. Understanding these interactions might also be
valuable to guide new treatment developments.
DIAGNOSIS
As mentioned previously, although knowing ApoE status is valu-
able to assess pre-symptomatic risk for disease, it is rarely suf-
ficient to make a diagnosis. Type III dysbetalipoproteinemia
diagnosis, a rare inherited disorder caused by ApoE (commonly
ApoE2) defective binding to lipoprotein receptor, is however an
exception (Mahley et al., 1999). Type III is mainly—but not
exclusively—diagnosed among individuals who are homozygous
for the apolipoprotein e2 allele (ApoE2/2). Therefore, assessment
of ApoE genotype plays a critical role in type III dysbetalipopro-
teinemia diagnosis. However, only a minority of ApoE2/2 carriers
develops this disease. Furthermore, even in subjects who develop
the disease, the majority remain normolipidemic for decades,
particularly in the absence of additional primary or secondary
dyslipidemic factors. This last point supports the value of know-
ing the ApoE status in patients with a family history of type
III dysbetalipoproteinemia because by controlling, or preventing,
other dyslipidemic factors it is may be possible to postpone the
expression of the disease.
PROGNOSIS
In addition to affecting the risk for several diseases, ApoE can
influence the pattern of their progression. For instance in several
types of dementia, ApoE4 has been related to earlier onset as well
as higher risk of neuropsychiatric symptoms (Leduc et al., 2011;
Panza et al., 2012). An obvious example is in AD were ApoE4
carriers develop dementia 8–20 years earlier then non-carriers
(Corder et al., 1993; Mahley and Huang, 2012a). ApoE4 is also
associated with an increased risk of dementia in Parkinson dis-
ease, Lewy body disease, Pick’s disease, vascular diseases, Down’s
syndrome, corticobasal degeneration, and HIV (Mahley et al.,
2009; Leduc et al., 2011; Verghese et al., 2011). While ApoeE4
does not appear to increase risk for depression per se (Mauricio
et al., 2000; Blazer et al., 2002), it has been associated with an
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increased risk for dementia in individuals with depression (Irie
et al., 2008; Kim et al., 2010, 2011; Meng and D’Arcy, 2013).
Except for AD, these findings suggest that ApoE might not be
associated with the disease pathology itself, but that ApoE4makes
the brain less resiliant to neurodegenerative processes. Knowing
the ApoE genotype of a person with a neurodegenerative disease
might therefore give insight on the risk of developing demen-
tia. Regular cognitive evaluations might be appropriate in such
cases.
The interaction between neurodegenerative diseases such as
AD and ApoE genotype on rate of cognitive decline have been
extensively studied, but the findings are inconsistant. While some
studies suggest that ApoE4 AD carriers have a faster rate of cog-
nitive decline (Craft et al., 1998; Martins et al., 2005; Schmidt
et al., 2012), others suggest no association (Growdon et al., 1996;
Kleiman et al., 2006). It has even been proposed that non-carriers
present a slightly different, and more agressive, form of AD and
that the latter group shows a faster progression than the ApoE4
carriers (Stern et al., 1997). In regard to persons with mild cogni-
tive impairment, the presence of an e4 allele is associated with
an increased risk of progression to dementia (Mosconi et al.,
2004; Petersen et al., 2005; Vos et al., 2013). In such cases, know-
ing the ApoE status seems to give useful information about the
prognosis. Because mild cognitive impairment can be caused by
several conditions such as AD, vascular disease, Parkinson disease,
and depression (Gauthier et al., 2006; Villeneuve et al., 2011a,b,
2012), knowing the ApoE status could also give insight about the
source of disease. Indeed, as mentioned previously ApoE4 is the
strongest genetic risk factor for AD and ApoE4 carriers often have
higher Aβ burden. Accordingly, ApoE4 carriers with mild cogni-
tive impairment are usually considered at increased risk of AD
(Petersen et al., 2005).
Knowledge of ApoE genotype also provides valuable infor-
mation about recovery prognosis after an acute event such as
stroke (Martinez-Gonzalez and Sudlow, 2006; Guo et al., 2011),
delirium (Adamis et al., 2007), or traumatic brain injury (TBI)
(Lichtman et al., 2000; Crawford et al., 2009; Mahley et al., 2009;
Ponsford et al., 2011). In all these cases, ApoE4 carriers show a
worse long-term outcome than ApoE3 carriers, and even some-
times higher risk of death. The presence of an e4 allele has also
been associated with greater cognitive decline in older stroke
patients (Ballard et al., 2004). A predominant hypothesis in the
literature is that this poor outcome is caused by a lack of repar-
ative capacity of ApoE4 (Crawford et al., 2009; Ponsford et al.,
2011). Given this knowledge, after an adverse event ApoE4 car-
riers should have a closer follow-up and older adults should be
assessed for associated cognitive deficits.
The value of knowing the ApoE status in the prediction of dis-
ease prognosis is not restricted to neurodegenerative diseases or
brain integrity as can be seen in Table 1. ApoE4 patients affected
by HIV are for instance at higher risk of developing peripheral
neuropathy and acquired immunodeficiency syndrome (AIDS).
Higher cerebrospinal fluid (CSF) ApoE levels have also been asso-
ciated with higher cognitive impairment in patients affected by
HIV (Andres et al., 2011), a finding that was also present in
persons with mild cognitive impairment (Song et al., 2012) but
not in AD patients (Schmidt et al., 2014). In addition, ApoE4/4
carriers suffering from AIDS have accelerated disease progression
and increased risk of death (Corder et al., 1998; Zhang et al.,
2011). These data suggest that, in regard to many diseases, a
closer follow-up is needed in ApoE4 carriers since this genotype
is associated with worst prognosis.
TREATMENT
ApoE AND DOSE RESPONSE
It is well known that genetics influence drug absorption, distri-
bution, and metabolism, leading to differences in dose responses
and side effects. Several reports suggest that ApoE alleles influ-
ence therapy efficiency for dyslipidemias (Brisson et al., 2002;
Nieminen et al., 2008; Dergunov, 2011). In fact, ApoE geno-
type is considered the most significant predictor of lipid response
to statins and fibrates, two classes of lipid-lowering therapy
which act via different mechanisms (Dergunov, 2011). While
individuals with ApoE4 seem to have the poorest response to
lipid-lowering therapy, individuals with ApoE2 have the highest
response (Dergunov, 2011). This result has been shown using
different molecules (Ordovas et al., 1995; Nestel et al., 1997;
Sanllehy et al., 1998; Ballantyne et al., 2000; Pedro-Botet et al.,
2001; Zuccaro et al., 2007) and has been replicated in familial
hypercholesterolemia patients (O’Malley and Illingworth, 1990;
Carmena et al., 1993). Phenotypic differences in lipid metabolism
may help explain these findings (Weisgraber et al., 1982; Mahley,
1988; Dong et al., 1994; Dong and Weisgraber, 1996; Petersen
et al., 2005; Hatters et al., 2006).
Assessing ApoE polymorphism might be particularly impor-
tant in clinical trials. In a Phase IIB clinical trial of an anti-diabetic
drug, rosiglitazone, to target mild to moderate AD patients,
the results were inconclusive when patients with and without
ApoE4 were pooled together (Risner et al., 2006). However,
when ApoE4 carriers were subtracted from the analysis, a signifi-
cant cognitive improvement was observed in ApoE4 non-carriers
(Risner et al., 2006). A recent clinical trial of Bapineuzumab, an
anti-amyloidβ monoclonal antibody, conducted in mild to mod-
erate AD patients reported reduction in cerebral Aβ and CSF
phospho-tau concentrations in ApoE4 carriers, but not in non-
carriers (Salloway et al., 2014). Turning to the cholinergic system,
response profiles of ApoE4 carriers have been mixed in AD
patients with dementia (Poirier et al., 1995; Farlow et al., 1996,
1998; Bizzarro et al., 2005; Choi et al., 2008; Carriere et al., 2009),
but non-demented ApoE4 carriers have shown greater cognitive
response to the cholinesterase inhibitor, donepezil (Petersen et al.,
2005), and to the cholinergic agonist, nicotine (Marchant et al.,
2010; Evans et al., 2013). The severity of the disease might there-
fore also be an important factor to consider when assessing these
relationships.
The effect of ApoE on response to treatment in other diseases is
not clear and/or research is lacking (Stehle et al., 2008; Carmona
et al., 2011; Guerrero et al., 2011). One interseting finding that
deserves to be mentioned is that, following chemotherapy, ApoE4
carriers are at increased risk of cognitive deficits (Ahles et al.,
2003). In the same line, older ApoE4 carriers are at increased risk
of delirium following surgery (Leung et al., 2007). The assessment
of ApoEmight therefore help guide the choice of treatment or give
knowledge about potential side effects.
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In addition to orienting treatment management, a better com-
prehension of disease interaction with gene variants may eventu-
ally help to create new treatments. A novel approach that is getting
increasing attention is the potential conversion of ApoE4 into a
molecule that is structurally and functionally similar to ApoE3
(or ApoE2). Recent studies that have investigated small molecules
to block domain interaction in ApoE4, have largely been suc-
cessful in preventing the deleterious effects associated with E4
(Mahley and Huang, 2012b; Liu et al., 2013). Other strategies,
such as using drugs that promote ApoE levels, increase the ABC
1 expression, increase ApoE receptor 2, or restore brain vascular
integrity might also be potential targets (Champagne et al., 2003;
Bu, 2009; Liu et al., 2013). Cyclophilin A for instance seems to be
a valuable target to offset the negative impact of ApoE4 on BBB
and potentially improve, or reverse, microvascular, and cerebral
blood flow reduction (Bell et al., 2012). Because neurovascular
defects can initiate neuronal dysfunction and neurodegenerative
changes, such treatment might be valuable to prevent or slow
down neurodegeneration in older adults. As previously men-
tioned, preventing BBB breakdown might also have a positive
effect on Aβ accumulation (Deane et al., 2008; Bell and Zlokovic,
2009). Even if research on these new therapeutic approaches is
not yet accessible in humans, their potential therapeutic implica-
tions have already created enthusiasm in the scientific community
(Bu, 2009; Ramaswamy and Kordower, 2011; Mahley and Huang,
2012a).
ApoE, NUTRIGENETIC, AND LIFESTYLE
Interestingly, while ApoE4 carriers are usually least sensitive to
statins, they are highly responsive to reduced fat diets. A sys-
tematic review conducted in 2003 suggests that ApoE4 carri-
ers tend to show the greatest decrease in LDL-cholesterol and
total-cholesterol following dietary changes (Masson et al., 2003).
Saito et al. reported similar results in patients with type 2 dia-
betes after a 14 day reduced fat diet therapy, showing a mean
reduction of 15.6% for LDL-cholesterol and of 16.3% for total
cholesterol in the ApoE3/4 group compared to 0.7 and 6.6%,
respectively in the ApoE3/3 group (Saito et al., 2004). Variation
in HDL-cholesterol following a diet rich in polyunsaturated fat
is unclear (Masson et al., 2003; De Andrade et al., 2010); how-
ever, physical activity, particularly in ApoE4 carriers (Bernstein
et al., 2002), increases HDL cholesterol (Marrugat et al., 1996;
Kokkinos and Fernhall, 1999). These findings are encourag-
ing because they suggest that alternative and/or complementary
approaches can be use to control metabolic variation in ApoE4
carriers.
As is well known, the lipid profile of a person has important
implications for CVDdevelopment. Controlling lipid levels might
also have a beneficial effect for AD prevention. In a recent in vivo
study it was shown that increased LDL cholesterol was associated
with increased brain Aβ levels (Reed et al., 2014). Higher HDL
cholesterol levels have also been found to be protective against
atrophy in brain regions vulnerable to AD (Villeneuve et al.,
2014). Therefore, knowing the ApoE genotype of a person might
influence the type of treatment proposed, or at least highlights
the importance of incorporating lifestyle changes as part of an
intervention plan.
ApoE GENOTYPE AND COMPLIANCE TO TREATMENT
In addition to the drug response dosage, the APOE genotype
might influence adherence to treatment, a primary concern in
medicine (Maitland-Van Der Zee et al., 2003). Indeed, in a
population-based study, Maitland-van der Zee et al. found that
subjects with ApoE4/4 genotype had a 2.28-fold increased risk of
ending a statin therapy when compared to individuals with the
ApoE3/3 genotype (Maitland-Van Der Zee et al., 2003). This risk
was predominant among men. Unfortunately, the reasons for dis-
continuing statin were not explored, however adverse side effects
is the principal reason for discontinuing antihyperlipidemic ther-
apy (Andrade et al., 1995). ApoE carriers in theMaitland-Van Der
Zee et al. study showed a trend toward higher dosage when com-
pared to the other genotypes, which might have resulted in more
severe side effects (Maitland-Van Der Zee et al., 2003). It is also
possible that ApoE4 genotype is associated with more side effects
independently of dosage as this has been found in other diseases
(De La Fuente-Fernandez et al., 1999; Porrata-Doria et al., 2010).
The second most frequent reason for ending therapy is thera-
peutic inefficacy (Andrade et al., 1995). Again, this reason might
explain why ApoE4 is associated with an increased risk of drug
discontinuation given the well-known lower response of ApoE4
carriers to treatment (Nieminen et al., 2008).
CONCLUSIONS
This review gives evidence that ApoE genotype affects pre-
symptomatic risk, diagnosis, prognosis, and treatment response
for a variety of diseases. Despite these multiple associations,
its inclusion in personalized medicine faces a major challenge
because for most if not all diseases, ApoE is a risk and not a causal
factor, and the many inconsistent findings in the literature suggest
that ApoE-associated diseases are the result of complex inter-
actions. Inclusion of ApoE in personalized medicine might be
most effective as part of a broader panel of information. Likewise,
the decision to assess ApoE genotype may best be made on a
case-by-case basis.
Understanding the source of ApoE-interactions might yield
great potential for disease prevention. It could be particularly
important in patients with a family history of type III dysbetal-
ipoproteinemia because by preventing other dyslipidemic factors
it may be possible to postpone or stop symptomatic expression
of the disease. Increasing evidence also suggests that improving
one’s lifestyle might help delay onset of AD and CVD. In such
cases, one could however argue that good lifestyle habits should
be promoted irrespective of genotype, and that assessing ApoE
status would therefore not be needed. Even if this is correct, know-
ing that actions can be taken to modify a genetic risk is valuable,
particularly in diseases such AD where no treatment is currently
available.
In regard to treatment, ApoE status would probably not
change the initial treatment plan, but this genetic information
might help to guide recommendations for alternative treatments
in cases of limited drug efficacy or adverse side effects. For
instance, while ApoE4 carriers appear to be less responsive to
lipid lowering therapy, they are more sensitive to diet and phys-
ical activity. Therefore, genotype specific treatment plans could
be introduced as part of clinical care when a person displays
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suboptimal response to common treatments. ApoE genotype
information could also be used to inform treatment in specific
circumstances. For example, if a medical team is considering
the pros and the cons of performing surgery in a frail older
adult, knowing the patient’s ApoE status could inform the deci-
sion. An ApoE4 carrier might be advised against the surgery.
One area where ApoE should certainly be included is in clinical
trials, particularly those concerning CVD and AD, as ApoE sta-
tus clearly affects outcome. Following from this, ApoE could be
used a target for new drug interventions given its broad range of
action.
Ethical implications of ApoE genotyping should also be con-
sidered. For instance, what are the implications of disclosing that
a person is an ApoE4/4 carrier? On one hand, the patient might be
motivated to modify environmental factors that are within their
control in order to reduce risk of associated diseases. On the other
hand, the stress and potential adverse consequences caused by this
information might be more detrimental than beneficial. There is
not a large evidence base examining the psychological effects of
disclosure, however in individuals with a familial history of AD,
disclosure of their ApoE genotype did not increase distress for e4-
carriers and indeed reduced it for non-e4 carriers (Green et al.,
2009). It is also important to address whether genetic informa-
tion would be available to health insurance companies, as this
could profoundly affect access to care. Finally, one major concern
raised about testing for ApoE genotype is that patients would be
over-diagnosed and over-treated.
In conclusion, the effect of ApoE on disease risk is com-
plex, however knowing the ApoE status of a person along with
medical and family history, medication, and lifestyle could give
valuable information for personalized medicine. More research
into understanding the factors and mechanisms involved in
ApoE-related interactions could improve awareness of disease
susceptibility, prevention strategies, and guide person-centered
therapeutic approaches.
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